


Introduction & Aim



Material & Methods

For all strains of *Staphylococcus* spp. with a Vitek2® LVX MIC > 0.12 mg/L and ≤ 1 mg/L, isolated from PJI or diabetic foot infections (DFI) → E-test® MIC determination for ciprofloxacin (CIP) and norfloxacin (NXN) disc diffusion test, and comparison of the results with LVX MIC value obtained using Vitek2® technology with the P-668 card


From Feb 2025 to Jan 2026

LVX MIC mg/L	≤ 0,12	0,25	0,5	1	2	4	> 4
Strain number	158	144	30	5	1	26	21

Table 1 : LVX CMI Vitek2® for all strains involved in PJI and DFI during the study period

* 150 *S. aureus*, 6 *S. capitis*, 3 *S. caprae*, 1 *S. cohnii*, 8 *S. epidermidis*, 11 *S. lugdunensis*

n = 179 strains* → Screening for low-level FQ resistance



Results

LVX MIC (mg/L) Vitek2®	n	Number of strains with low-level avec FQ resistance ph��notype (%)
0,25	144	0
0,5	30	4 (13 %)
1	5	3 (60 %)

Table 2 : Distribution of *Staphylococcus* spp. strains with FQ low-level resistance phenotype according to LVX CMI obtained via the P-668 card with Vitek 2® technology

Species	LVX CMI Vitek2®	CIP MIC E-test®	NXN diameter
<i>S. aureus</i>	0.5	1.5	15
<i>S. aureus</i>	0.5	1.5	16
<i>S. aureus</i>	1	2	12
<i>S. aureus</i>	0.5	2	16
<i>S. aureus</i>	1	2	15
<i>S. aureus</i>	0.5	1.5	16
<i>S. aureus</i>	1	2	14

Table 3 : LVX & CIP MICs and NXN diameter for strains considered as expressing a low-level FQ resistance phenotype

Conclusion

- ✓ *Staphylococcus* spp. strains with a Vitek2® LVX MIC ≤ 0.25 mg/L → no strain with a low-level FQ resistance phenotype
- ✓ No contraindication to the FQ use for the patient’s management with PJI or DFI
- ✓ Strains with Vitek2® MICs of 0.5 and 1 mg/L → the risk of low-level resistance appears to increase with the LVX MIC value
- ✓ A check for the absence of low-level resistance using a diffusion test (NXN disc) is mandatory